Pelthos Therapeutics Inc.(PTHS)Earnings, Financials & Key Ratios
PTHS•NYSE
$25.00
$15M mkt cap·Price updated May 6, 2026
AboutPelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.Show more
- Revenue$0
- EBITDA-$7M-4.5%
- Net Income-$8M-7.8%
- EPS (Diluted)-13.54-5.8%
- Interest Coverage-9.63+27.3%
PTHS Key Insights
Pelthos Therapeutics Inc. (PTHS) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PTHS Price & Volume
Pelthos Therapeutics Inc. (PTHS) stock price & volume — 10-year historical chart
Loading chart...
PTHS Growth Metrics
Pelthos Therapeutics Inc. (PTHS) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-134.23%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-102.62%
Return on Capital
10 Years-
5 Years-
3 Years-
Last Year-
PTHS Peer Comparison
Pelthos Therapeutics Inc. (PTHS) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 COLL | 1.18B | 36.51 | 21.10 | 23.62% | 8.05% | 24.11% | 3.12 | |
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 | |
 SUPN | 2.96B | 51.45 | -75.66 | 8.63% | -3.74% | -2.73% | 0.04 | |
 LNTH | 5.61B | 86.15 | 25.26 | 0.5% | 15.15% | 20.58% | 0.00 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ACAD | 3.68B | 21.48 | 9.38 | 11.87% | 36.49% | 41.9% | 0.04 | |
 INVA | 1.91B | 22.52 | 6.82 | 18.52% | 118.91% | 46.47% | 0.23 | |
 PCRX | 931.85M | 23.69 | 148.06 | 3.63% | 1.27% | 1.31% | 0.66 |
Compare PTHS vs Peers
Pelthos Therapeutics Inc. (PTHS) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PTHS Income Statement
Pelthos Therapeutics Inc. (PTHS) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 7.41M |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 3.38M |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 4.02M▲ 0% |
| Gross Margin % | - | - | - | 54.31% |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 2.32M | 6.86M | 7.57M | 26.27M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 1.93M | 4.28M | 6.39M | 25.13M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 391.73K | 2.58M | 1.18M | 1.14M |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | -2.32M▲ 0% | -6.86M▼ 196.0% | -7.57M▼ 10.3% | -22.25M▲ 0% |
| Operating Margin % | - | - | - | -300.45% |
| Operating Income Growth % | - | -196.02% | -10.33% | - |
| EBITDA | -2.32M | -6.86M | -7.17M | -21.1M |
| EBITDA Margin % | - | - | - | -284.95% |
| EBITDA Growth % | - | -196.02% | -4.47% | -128.66% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 1.14M |
| EBIT | -2.32M | -6.86M | -7.17M | -22.24M |
| Net Interest Income | -140.43K | -518.51K | -786.39K | -1.8M |
| Interest Income | 0 | 0 | 0 | 5K |
| Interest Expense | 140.43K | 518.51K | 786.39K | 1.81M |
| Other Income/Expense | -140.43K | -518.51K | -383.89K | -1.79M |
| Pretax Income | -2.46M▲ 0% | -7.38M▼ 200.2% | -7.96M▼ 7.8% | -24.05M▲ 0% |
| Pretax Margin % | - | - | - | -324.69% |
| Income Tax | 0 | 0 | 0 | -465K |
| Effective Tax Rate % | 0% | 0% | 0% | 1.93% |
| Net Income | -2.46M▲ 0% | -7.38M▼ 200.2% | -7.96M▼ 7.8% | -23.58M▲ 0% |
| Net Margin % | - | - | - | -318.41% |
| Net Income Growth % | - | -200.2% | -7.78% | -134.23% |
| Net Income (Continuing) | -2.46M | -7.38M | -7.96M | -23.58M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -4.26▲ 0% | -12.80▼ 200.5% | -13.54▼ 5.8% | -36.82▲ 0% |
| EPS Growth % | - | -200.47% | -5.78% | -102.62% |
| EPS (Basic) | -4.26 | -12.80 | -13.54 | - |
| Diluted Shares Outstanding | 576.75K | 576.75K | 587.62K | 640.52K |
| Basic Shares Outstanding | 576.75K | 576.75K | 587.62K | 640.52K |
| Dividend Payout Ratio | - | - | - | - |
PTHS Balance Sheet
Pelthos Therapeutics Inc. (PTHS) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Total Current Assets | 55.07K | 96.39K | 1.37M | 49.05M |
| Cash & Short-Term Investments | 55.07K | 96.39K | 513.44K | 14.25M |
| Cash Only | 55.07K | 96.39K | 513.44K | 14.25M |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 40.4K | 7.99M |
| Days Sales Outstanding | - | - | - | 99.91 |
| Inventory | 0 | 0 | 0 | 24.1M |
| Days Inventory Outstanding | - | - | - | 649.75 |
| Other Current Assets | 0 | 0 | 750K | 1.16M |
| Total Non-Current Assets | 0 | 0 | 0 | 77.38M |
| Property, Plant & Equipment | 0 | 0 | 0 | 13.53M |
| Fixed Asset Turnover | - | - | - | 2.19x |
| Goodwill | 0 | 0 | 0 | 30.63M |
| Intangible Assets | 0 | 0 | 0 | 32.52M |
| Long-Term Investments | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 711K |
| Total Assets | 55.07K▲ 0% | 96.39K▲ 75.0% | 1.37M▲ 1320.4% | 126.43M▲ 0% |
| Asset Turnover | - | - | - | 0.23x |
| Asset Growth % | - | 75.02% | 1320.41% | 6983% |
| Total Current Liabilities | 3.76M | 6.54M | 4.08M | 24.77M |
| Accounts Payable | 2.99M | 4.62M | 1.9M | 5.67M |
| Days Payables Outstanding | - | - | - | 408.67 |
| Short-Term Debt | 540.43K | 1.27M | 2.19M | 631K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 1.02M |
| Other Current Liabilities | 221.88K | 645.95K | 0 | 17.45M |
| Current Ratio | 0.01x | 0.01x | 0.34x | 0.34x |
| Quick Ratio | 0.01x | 0.01x | 0.34x | 0.34x |
| Cash Conversion Cycle | - | - | - | 340.99 |
| Total Non-Current Liabilities | 0 | 0 | 0 | 43.41M |
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 2.85M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 12.87M |
| Other Non-Current Liabilities | 0 | 0 | 0 | 26.18M |
| Total Liabilities | 3.76M | 6.54M | 4.08M | 68.18M |
| Total Debt | 540.43K | 1.27M | 2.19M | 3.48M |
| Net Debt | 485.36K | 1.17M | 1.67M | -10.77M |
| Debt / Equity | - | - | - | 0.06x |
| Debt / EBITDA | - | - | - | -0.16x |
| Net Debt / EBITDA | - | - | - | 0.51x |
| Interest Coverage | -16.51x | -13.23x | -9.63x | -12.31x |
| Total Equity | -3.71M▲ 0% | -6.44M▼ 73.9% | -2.71M▲ 57.9% | 58.25M▲ 0% |
| Equity Growth % | - | -73.87% | 57.89% | 309.29% |
| Book Value per Share | -6.43 | -11.17 | -4.62 | 90.95 |
| Total Shareholders' Equity | -3.71M | -6.44M | -2.71M | 58.25M |
| Common Stock | 111 | 391 | 613 | 0 |
| Retained Earnings | -6.14M | -13.52M | -21.47M | -43.13M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
PTHS Cash Flow Statement
Pelthos Therapeutics Inc. (PTHS) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Cash from Operations | -1.57M | -981.03K | -5.79M | -5.79M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | 37.4% | -490.45% | -8411.34% |
| Net Income | -2.46M | -7.38M | -7.96M | -23.58M |
| Depreciation & Amortization | 0 | 0 | 0 | 1.14M |
| Stock-Based Compensation | 110.15K | 1.73M | 1.8M | 1.43M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 140.43K | 2.62M | 328.93K | 5.21M |
| Working Capital Changes | 640.86K | 2.05M | 34.63K | -1.2M |
| Change in Receivables | 0 | 0 | -45.79K | -7.94M |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 413.6K | 1.63M | 1.18M | 4.65M |
| Cash from Investing | 0 | 0 | 0 | 2.76M |
| Capital Expenditures | 0 | 0 | 0 | 0 |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 2.76M |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 1.62M | 1.02M | 6.21M | 27.25M |
| Debt Issued (Net) | 400K | 766.94K | 321.43K | -305.82K |
| Equity Issued (Net) | 0 | 255.41K | 1000K | 1.08M |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | -166.51K | 0 |
| Other Financing | 1.22M | 0 | 0 | 0 |
| Net Change in Cash | 55.07K▲ 0% | 41.32K▼ 25.0% | 417.05K▲ 909.4% | 12.93M▲ 0% |
| Free Cash Flow | -1.57M▲ 0% | -981.03K▲ 37.4% | -5.79M▼ 490.4% | -17.01M▲ 0% |
| FCF Margin % | - | - | - | -229.66% |
| FCF Growth % | - | 37.4% | -490.45% | -210.42% |
| FCF per Share | -2.72 | -1.70 | -9.86 | -9.86 |
| FCF Conversion (FCF/Net Income) | 0.64x | 0.13x | 0.73x | 0.72x |
| Interest Paid | 0 | 0 | 0 | 18.75K |
| Taxes Paid | 0 | 0 | 0 | 0 |
PTHS Key Ratios
Pelthos Therapeutics Inc. (PTHS) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | TTM |
|---|---|---|---|
| Return on Equity (ROE) | - | - | -40.48% |
| Return on Invested Capital (ROIC) | - | - | -165.37% |
| Gross Margin | - | - | 54.31% |
| Net Margin | - | - | -318.41% |
| Debt / Equity | - | - | 0.06x |
| Interest Coverage | -13.23x | -9.63x | -12.31x |
| FCF Conversion | 0.13x | 0.73x | 0.72x |
PTHS Frequently Asked Questions
Pelthos Therapeutics Inc. (PTHS) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Pelthos Therapeutics Inc. (PTHS) reported $7.4M in revenue for fiscal year 2024.
Pelthos Therapeutics Inc. (PTHS) grew revenue by 0.0% over the past year. Growth has been modest.
Pelthos Therapeutics Inc. (PTHS) reported a net loss of $23.6M for fiscal year 2024.
Dividend & Returns
Pelthos Therapeutics Inc. (PTHS) had negative free cash flow of $17.0M in fiscal year 2024, likely due to heavy capital investments.
Explore More PTHS
Pelthos Therapeutics Inc. (PTHS) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates